The company: FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with
A record notice: the source is linked, and no summary was written because none passed the fact check.
FDA
3 stories
A record notice: the source is linked, and no summary was written because none passed the fact check.
FDA
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
An independent monitoring committee concluded the trial was unlikely to show an overall survival benefit, prompting Geron to end the study on October 28, 2026.
SEC filing